1019380-80-3

Basic information

• Product Name: 1-[1-(2,4-dichlorobenzyl)piperidin-4-yl]methanamine
• Synonyms: 1-[1-(2,4-dichlorobenzyl)piperidin-4-yl]methanamine
• CAS NO: 1019380-80-3
• Molecular Weight: 273.205
• Mol File: 1019380-80-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-[1-(2,4-dichlorobenzyl)piperidin-4-yl]methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[1-(2,4-dichlorobenzyl)piperidin-4-yl]methanamine(1019380-80-3)
• EPA Substance Registry System: 1-[1-(2,4-dichlorobenzyl)piperidin-4-yl]methanamine(1019380-80-3)

Safety Data

• Hazardous Substances Data: 1019380-80-3(Hazardous Substances Data)

Upstream product

• 71207-29-9 N-hexahydro-4-pyridinylmethyl-N-phenylmethylidenamine 

Downstream Products

• 1452520-13-6 N-{ [1-(2,4-dichlorobenzyl)piperidin-4-yl]methyl}-5-methoxy-1H-indazole-3-carboxamide 

Relevant articles and documents

Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders

Novel treatments for bipolar disorder with improved efficacy and broader spectrum of activity are urgently needed. Glycogen synthase kinase 3β (GSK-3β) has been suggested to be a key player in the pathophysiology of bipolar disorder. A series of novel GSK-3β inhibitors having the common N-[(1-alkylpiperidin-4-yl)methyl]-1H-indazole-3-carboxamide scaffold were prepared taking advantage of an X-ray cocrystal structure of compound 5 with GSK-3β. We probed different substitutions at the indazole 5-position and at the piperidine-nitrogen to obtain potent ATP-competitive GSK-3β inhibitors with good cell activity. Among the compounds assessed in the in vivo PK experiments, 14i showed, after i.p. dosing, encouraging plasma PK profile and brain exposure, as well as efficacy in a mouse model of mania. Compound 14i was selected for further in vitro/in vivo pharmacological evaluation, in order to elucidate the use of ATP-competitive GSK-3β inhibitors as new tools in the development of new treatments for mood disorders.

USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS

1 H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1 H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-33) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.